Photo by nci from unsplash
https://doi.org/10.1016/j.clml.2015.07.635. 4. Dolai TK, Mukherjee S, Mandal PK, De R, Chakrabarti P. A prospective study to evaluate the efficacy, safety and response duration of newly diagnosed adult immune thrombocytopenia patients… Click to show full abstract
https://doi.org/10.1016/j.clml.2015.07.635. 4. Dolai TK, Mukherjee S, Mandal PK, De R, Chakrabarti P. A prospective study to evaluate the efficacy, safety and response duration of newly diagnosed adult immune thrombocytopenia patients treated with low dose rituximab and high dose of dexamethasone. Blood. 2016;128(22):4921 http://www. bloodjournal.org/content/128/22/4921. Accessed October 14, 2018. 5. Khellaf M, Charles-Nelson A, Fain O, et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood. 2014;124(22):3228-3236. https://doi.org/10.1182/blood-2014-06-582346. 6. Westwood J-P, Thomas M, Alwan F, et al. Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens. Blood Adv. 2017;1(15):1159-1166. https://doi.org/10.1182/bloodadvances.2017008268.
Journal Title: American Journal of Hematology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!